RESUMO
The number of allogeneic hematopoietic SCTs performed globally each year continues to increase, paralleled by an increased demand for donors of therapeutic cells. Donor characteristics and collection procedures have undergone major changes during recent decades, and further changes are foreseen. Information on short- and long-term donor outcomes is of crucial importance to ensure maximal donor safety and availability. Current data, predominantly from unrelated donors, give reliable information on the frequent early events associated with donation-most of them of mild-to-moderate intensity. Information on the type and relative risk of serious adverse reactions is more limited. Moreover, only few data exist on long-term donor outcome. On the basis of this need, recommendations for a minimum data set for prospective donor follow-up were developed in a workshop with the participation of an international group of investigators actively involved in allogeneic stem cell donation under the auspices of and approved by the Worldwide Network for Blood and Marrow Transplantation. Establishment of a standardized global follow-up for both, related and unrelated, donors will enable monitoring of the short- and long-term safety profiles of hematopoietic cell donation and form a solid basis for future donor selection and counseling.
Assuntos
Transplante de Células-Tronco Hematopoéticas/métodos , Células-Tronco Hematopoéticas/citologia , Doadores de Tecidos , Adolescente , Adulto , Seleção do Doador , Humanos , Pessoa de Meia-Idade , Transplante Homólogo , Adulto JovemRESUMO
Since the beginning of hematopoietic stem cell harvesting from volunteer unrelated donors, ensuring donor safety has been a necessary goal of all parties involved in the process. As donation of BM or PBSCs is not in the interest of the donor's own physical health, donor registries and transplantation centers must take into account both medical and ethical aspects involved in the donation procedure. One of the principal goals leading to the formation of the World Marrow Donor Association (WMDA) was to establish internationally acceptable standards for all aspects of unrelated donor care.
Assuntos
Transplante de Células-Tronco Hematopoéticas/normas , Internacionalidade , Segurança , Doadores de Tecidos , Obtenção de Tecidos e Órgãos/ética , Obtenção de Tecidos e Órgãos/normas , Coalizão em Cuidados de Saúde , Transplante de Células-Tronco Hematopoéticas/ética , Humanos , Sistema de Registros/normas , Doadores de Tecidos/ética , Obtenção de Tecidos e Órgãos/organização & administração , Transplante HomólogoRESUMO
The World Marrow Donor Association (WMDA) is an international organization fostering collaboration in clinical transplantation and promoting the interests of unrelated stem cell donors. The WMDA has developed standards for the recruitment, counseling, work-up and subsequent donations to protect the interests of donors. Although the care of family donors has been carefully considered and managed in transplant centers (TCs) internationally over numerous years (and increasingly TCs are facing accreditation programs, which address this issue) there is currently a lack of standardized guidelines for the management of family donors. The underlying principles of family donor care are in many ways identical to those concerning unrelated donors, although key ethical considerations differ. Although the WMDA is primarily involved in the field of unrelated donors, we believe that it is important to collaborate with those involved with family donors, to standardize the care. This document hopes to encourage increased collaboration between those caring for related and unrelated donors, and build on the extensive work, which has already been undertaken in this field to homogenize care. We recognize that there will be financial, regulatory and logistic differences in different countries and that the manner in which these principles are achieved may vary.
Assuntos
Transplante de Células-Tronco Hematopoéticas/normas , Agências Internacionais , Doadores Vivos , Transplante de Medula Óssea/normas , Família , Humanos , Cooperação Internacional , Guias de Prática Clínica como Assunto/normasRESUMO
In unrelated hematopoietic stem cell transplantation (HSCT), human leukocyte antigen (HLA)-C locus incompatibilities occur frequently and are associated with increased risk of posttransplant complications. Because HLA-B51 is associated with a high rate of Cw disparities, we performed a comprehensive four-digit typing analysis of 140 ABCDRB1 B51 genotypes proven by pedigree analysis and 311 unrelated donors selected for 75 B51-positive patients. In addition, 145 A1/Ax-B8/B51-DR3/DRx donors were HLA typed at a high-resolution level and tested for three microsatellite (Msat) polymorphisms located in the HLA class I and III regions. Based on these data sets, 182 different ABCDR haplotypes with 14 different B-Cw associations were detected. Rates of Cw mismatches were shown to be highly correlated with the ABDRB1 haplotypes. We have computed 21 B51 haplotypes that disclose a high probability of HLA-C allele matching and 30 haplotypes with a low (<25%) probability. The HLA-C allele frequency profiles were quite different in these two groups, with a more heterogeneous distribution in the low matching probability group. HLA-Cw*1502 was inversely correlated with the likelihood to identify a Cw-mismatched donor: it was present in 61% of the high vs 18% of the low probability group (P < 0.0001). The analysis of three Msats in the class I and III regions showed a higher allelic diversity in B51-positive haplotypes compared with the conserved A1-B8-DR3 haplotype. HLA-B51 haplotypes therefore exhibit a high diversity at the level of B-Cw associations and of non-HLA polymorphisms in the class I and III regions. Such heterogeneity negatively impacts on overall matching in HSCT.
Assuntos
Variação Genética , Antígenos HLA-B/genética , Haplótipos/genética , Transplante de Células-Tronco Hematopoéticas , Genética Populacional , Genótipo , Antígeno HLA-B51 , Antígenos HLA-C/genética , Teste de Histocompatibilidade , Humanos , Repetições de Microssatélites , Sistema de Registros , Doadores de TecidosRESUMO
It is currently unknown what degree of human leukocyte antigen (HLA)-mismatching is acceptable in unrelated donor hematopoietic stem cell transplantation (UD-HSCT). Mismatches at some loci may be more permissive than others. We have analyzed the effect of high-resolution HLA-matching on outcome of all 214 consecutive recipients of UD-HSCT carried out in Switzerland. All typing was by the Swiss reference laboratory. Donor-recipient pairs were HLA-10/10 matched (n=130) or mismatched for either HLA-A/-B/-DRB1/multiple loci (n=33; (HLA-A/-B=10); (-DRB1=8); (multiple=15)); HLA-C (n=29) or HLA-DQ/-DRB3 (n=22; (DQ=16); (-DRB1=6)). The median follow-up was 32 months. Survival probabilities (+/-95% confidence interval) at 3 years were 57 (+/-10)% for recipients of HLA 10/10-matched transplants, 53 (+/-22)% for recipients of HLA-DQ/-DRB3-mismatched transplants, 44 (+/-20)% for recipients of HLA-C-mismatched transplants and 0% for recipients of transplants mismatched at HLA-A/-B/-DRB1/multiple loci (P<0.0001). In multivariate analyses, HLA compatibility was the variable most significantly associated with survival and treatment-related mortality. We found important differences in survival in recipients of UD-HSCT with best results for transplants from 10/10 matched donors. Single mismatches at HLA-DQ/-DRB3 were well tolerated, mismatches at HLA-C had intermediate results and mismatches at HLA-A/-B/-DRB1/multiple loci resulted in poor survival.
Assuntos
Antígenos HLA/química , Teste de Histocompatibilidade/métodos , Histocompatibilidade , Transplante de Células-Tronco/métodos , Adolescente , Adulto , Criança , Pré-Escolar , Feminino , Humanos , Lactente , Doadores Vivos , Masculino , Pessoa de Meia-Idade , SuíçaRESUMO
119 collections of peripheral blood stem cells were performed in 60 patients suffering from various haematological malignancies. One patient was transplanted twice. Peripheral blood stem cell mobilisation was performed using various regimens. A correlation (r = 0.732) was found between the number of peripheral CD34+ cells and the number of CD34+ cells that were collected by apheresis. Furthermore, the number of collected peripheral blood stem cells correlated with the number of colony-forming units (CFU-GM) identified after cell culture (r = 0.607). After transplantation, the duration of neutropenia (> 0.5 x 10(9)/l) was 11.7 days (SD = 3.3) and of thrombocytopenia (> 20 x 10(9)/l) 12.7 days (SD = 6.8). For the whole group, no correlation was observed between the number of CD34+ cells infused and the length of the aplasia. However, when the patients were separated into two groups, according to the amount of CD34+ cells transplanted (< 10 x 10(6)/kg, n = 48 and > 10 x 10(6)/kg, n = 13), a statistically significant but moderate decrease in the duration of neutropenia and thrombocytopenia was observed in patients who received the highest doses of CD34+ cells. Our results confirm the utility of measuring the number of the CD34+ cells in peripheral blood as well as in the product collected by apheresis, but they challenge the place of cultures of progenitor haematopoietic cells. Moreover, the infusion of large amounts of CD34+ cells shortens the duration of the aplasia.
Assuntos
Antígenos CD34/sangue , Neoplasias Hematológicas/terapia , Transplante de Células-Tronco Hematopoéticas , Células-Tronco Hematopoéticas/classificação , Antígenos CD/sangue , Células Cultivadas , Ensaio de Unidades Formadoras de Colônias , Neoplasias Hematológicas/sangue , Mobilização de Células-Tronco Hematopoéticas , Transplante de Células-Tronco Hematopoéticas/efeitos adversos , Células-Tronco Hematopoéticas/imunologia , Humanos , Leucaférese , Neutropenia , Análise de Regressão , Trombocitopenia , Transplante AutólogoRESUMO
61 autologous transplantations for haematological malignancies have been performed with peripheral blood stem cells in 60 patients. 26 grafts were performed for non-Hodgkin's lymphoma (18 patients were transplanted in first remission, 8 patients after progression or relapse), 13 for multiple myeloma, 7 for Hodgkin's disease and 10 for acute myeloid leukaemia. One patient died from thrombosis of the portal vein. 38 patients were in complete remission 29 months (extremes: 14-44) after transplantation. 21 of 60 patients progressed or relapsed after transplantation, and 14 died. No death was attributed to graft failure, infection or haemorrhage. In conclusion, transplantation with peripheral blood stem cells is well tolerated, has a low toxicity rate, and can be used safely for patients with haematological malignancies.